

Provided by:



Melanoma and Cutaneous Malignancy Tumor Board 2023-2024

Melanoma and Cutaneous Malignancy Tumor Board 2023-2024 - 5/1/2024

May 1, 2024

12:00 PM - 1:00 PM

PCAM South Tower Room 10-124

Target Audience

This program has been designed for DERMATOLOGY, INTERNAL MEDICINE - Medical Oncology, PATHOLOGY - CLINICAL, RADIATION ONCOLOGY, OTOLARYNGOLOGY, DERMATOLOGY - Dermatopathology, PATHOLOGY - ANATOMIC, OBSTETRICS AND GYNECOLOGY - Gynecologic Oncology, PATHOLOGY - Dermatopathology, INTERNAL MEDICINE - Hospice and Palliative Medicine, SURGERY - Complex General Surgical Oncology

Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Discuss a multidisciplinary approach to care for patients with melanoma and other malignant skin diseases
- 2 Discuss how to provide a plan for accurate diagnosis, complete staging, and proper treatment for patients.
- 3 Describe how to treat and manage patients with melanoma and other cutaneous malignancies using both proven standardized methods and consider current investigative clinical trials.

Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physicians: Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*[™].

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC: up to 1 MOC points

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABPath MOC: up to 1 MOC points

Nurses: This activity is for 1.00 contact hours.

Pharmacists: This activity is not approved for pharmacy contact hours

For more information, please contact
Ahron Flowers, Samia White
(215) 360-0911, (215) 662-3002

aflow@pennmedicine.upenn.edu, Samia.White@Pennmedicine.upenn.edu

Check your transcript online at <https://upenn.cloud-cme.com>

PAs: Penn Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.

This activity is designated for **1.00** AAPA Category 1 CME credit(s). PAs should only claim credit commensurate with the extent of their participation.

Approved for (PSRM) patient safety/risk management designation

Acknowledgement of Commercial Support*

None

Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships (RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based, are based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant, and applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Alexander C Huang, MD	Other Planning Committee Member	Nothing to disclose - 04/16/2024
Michael Farwell, MD	Other Planning Committee Member	Grant or research support-Merck & Co Grant or research support-Bristol-Myers Squibb Grant or research support-ImaginAb Grant or research support-Carisma - 05/25/2023
Lynn M Schuchter, MD	Course Director, Faculty	Nothing to disclose - 09/12/2023
Ravi Amaravadi, MD	Other Planning Committee Member	Ownership-Pinpoint Therapeutics Advisor-Tasca Advisor-Deciphera Grant or research support-Novartis (Relationship has ended) Grant or research support-Deciphera Grant or research support-Springworks Grant or research support-Merck & Co Grant or research support-Bristol-Myers Squibb Grant or research support-Pinpoint Therapeutics Advisor-Immunacell - 11/06/2023
Kristin Kreider, PA-C	Physician Assistant Planner	Nothing to disclose - 02/14/2024
Giorgos Karakousis	Other Planning Committee Member	Advisor-Merck & Co (Relationship has ended) Grant or research support-Merck & Co - 11/02/2023
Tara C Mitchell, MD	Co-Director	Honoraria-Merck & Co Honoraria-Bristol-Myers Squibb Honoraria-Pliant Therapeutics (Relationship has ended) Honoraria-Pfizer (Relationship has ended) Honoraria-GigaGen

		(Relationship has ended) - 03/06/2024
Suzanne McGettigan	Nurse Planner	Speakers Bureau-Bristol-Myers Squibb Speakers Bureau-Merck & Co Consulting Fee-Pfizer, Inc. Speakers Bureau-Regeneron Pharmaceuticals, Inc. - 10/26/2023
Emily Chu, MD, PhD	Other Planning Committee Member	Nothing to disclose - 09/14/2023
John N Lukens, MD	Other Planning Committee Member	Nothing to disclose - 02/08/2024
Xiaowei Xu, MD, PhD	Other Planning Committee Member	Nothing to disclose - 04/16/2024
John Miura, MD	Other Planning Committee Member	Nothing to disclose - 09/15/2023
Grace Weyant, MD	Other Planning Committee Member	Nothing to disclose - 04/15/2024
Meghan Mulligan, CRNP	Other Planning Committee Member	Nothing to disclose - 01/31/2024
Joanna Walker, MD	Other Planning Committee Member	Nothing to disclose - 11/05/2023
Shannon Ugarte, MD	Other Planning Committee Member	Nothing to disclose - 08/30/2023
Eric Morgan, MD	Other Planning Committee Member	Nothing to disclose - 03/22/2024

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected